Business Wire

IMMERVISION

Share
Immervision Orders Investigation by Ad Hoc Research to Clearly See Smartphone Camera Performance from End Users Point of View

Immervision , the Montreal-based developer and licensor of patented, wide-angle optics and imaging technology, today announced its 2020 Smartphone Camera survey results in cooperation with Ad Hoc Research.

Amid confusing end-user comments on photos and videos and disagreement between phone makers on what has to be done, Immervision decided to investigate what end-user like or don’t like from their phone’s cameras. It revealed no smartphone brand, even the flagship brands, is performing well in consumers’ experience in taking photos.

The survey included 1,557 consumers located in California, China and South Korea who selected pictures they preferred amongst 10 images for each of the four scenes comprising city landscape and people. Photos were taken on settings from the same angle and under the same environmental conditions. Results were based on region, age, gender. Data was collected February 20 - March 5, 2020.

Ad Hoc Research said, “Our study showed that with current functionalities, none of the phones tested could adapt properly to all the scenes captured. Indeed, the user's preference varies according to the type of scene and the content photographed (people vs. static objects). For users to be more satisfied with one phone, there should be a better adjustment of camera specifications based on the scene, since a certain field of view or a standardized line correction is not appropriate in all contexts.”

The smartphones getting the highest consumer praises were Sony Xperia 1, Google Pixel 4 XL and Vivo NEX 3 5G. No one phone performs well in all scenes.

“Adapting to the scene is paramount. End-users are clear; no smartphone performs well in photos in all contexts: poor face proportions, distorted buildings and statues are the norm,” said Alessandro Gasparini, Executive Vice President, Operations and Chief Commercial Officer of Immervision. “The winners vary depending on the scene, which demonstrates the need for adaptive solution and not one fit for all to perfect the field of view and deliver better distortion correction.”

Key takeaways:

  • Scene content determined optimal field of view
  • Preserving human face proportions is always more important than straight lines
  • Consumers want more field of view when they feel they are missing something in the picture
  • In building photography, straight lines are usually better than curves
  • In some specific conditions, distortion on a landmark can be forgiving and score high
  • Preferred distortion is dependent on the objects present and their location in a scene

Contact Immervision to view the entire report.

About Immervision

Immervision enables intelligent vision in any device. Our Deep Seeing technology and renowned experts in wide-angle optical design and image processing enable smart devices with superhuman eyes to capture high quality visual and contextual data. We invent, customize and license wide-angle lenses and imaging software technology for AI, machine vision and user applications, from capture to display, in the mobile, automotive, robotics, security, and other industrial and consumer product industries. www.immervision.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye